[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ect\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ect":161},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,58,82,109,134],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":36,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":57},"100640612","flumazenil-for-benzodiazepine-reversal-in-electroconvulsive-therapy-100640612",false,"NCT07619092","Flumazenil for Benzodiazepine Reversal in Electroconvulsive Therapy","Flumazenil for Benzodiazepine Reversal in Electroconvulsive Therapy (FLEET): A Randomized Controlled Trial","FLEET","Inclusion criteria:\n\n* Current depressive episode (unipolar or bipolar), corresponding to ICD-10 codes F31.3-5, F32 or F33.\n* Admitted at a study affiliated department in the Mental Health Services of the Capital Region of Denmark\n* Referred to ECT by the regular psychiatrist and has given consent to ECT\n* Currently receiving treatment with a benzodiazepine and\u002For zopiclone, at a minimum daily dose equivalent to 0.5 mg lorazepam.\n\nExclusion criteria:\n\n* Involuntary treatment with ECT\n* Known gross abnormalities in brain structure deemed likely to influence cognitive functioning\n* Pregnancy or breast-feeding\n* Inability to read or understand Danish\n* Acute organic brain disease (e.g., delirium) influencing the ability to give informed consent\n* Any pre-existing condition associated with an increased risk of prolonged or uncontrollable seizures, including but not limited to epilepsy or alcohol- or benzodiazepine withdrawal states\n* Conditions associated with reduced metabolism of flumazenil (e.g., liver failure)","ALL","18 Years",{"count":20,"type":21},145,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this study is to investigate whether administering flumazenil to reverse the effects of benzodiazepines and\u002For zopiclone during electroconvulsive therapy (ECT) can help reduce cognitive side effects without diminishing treatment effectiveness in hospitalized patients with depression.\n\nThe investigators hypothesize that blockade of the GABA receptor with flumazenil will reduce cognitive side effects through improved seizures and a reduced need for electrical charge escalation during the ECT series. Cognitive side effects will be measured by the total score on the Screening for Cognitive Impairment in Psychiatry (SCIP) (primary outcome) at follow-up after completion of the ECT series. Furthermore, it is expected that the flumazenil strategy will reduce pre-treatment anxiety and improve patient satisfaction (secondary outcomes). In addition, flumazenil strategy is hypothesized to have beneficial effects on subjective cognitive complaints, autobiographical memory, and executive functioning (secondary outcomes). Finally, the flumazenil strategy is expected to be associated with more favorable structural and functional changes in executive functioning and memory-related brain networks after completion of the ECT series, which may, in turn, be linked to better overall cognition and autobiographical memory (secondary outcome measures). For exploratory purposes, the study will also examine longitudinal changes in depressive symptoms and cognitive outcomes from baseline to follow-up (tertiary outcomes).\n\nInvestigators will compare two different pre-ECT benzodiazepine management strategies:\n\n1. Flumazenil strategy (experimental): continued benzodiazepine and\u002For zopiclone use up until the time of the ECT session, followed by administration of flumazenil immediately prior to ECT\n2. Benzodiazepine withholding strategy (treatment as usual):\n\ndiscontinuation of benzodiazepines and\u002For zopiclone prior to the ECT in accordance with standard clinical practice",[27,28,29,30,31,32,33,34,35],"Depression - Major Depressive Disorder","Bipolar Disorder (BD)","Functional Magnetic Resonance Imaging (fMRI)","Cognition","Autobiographical Memory","Electroconvulsive Therapy","ECT","Treatment Outcome","Inpatients",[37,38,39,40,41,42,35,43,44,34,30],"flumazenil","benzodiazepine reversal","electroconvulsive therapy","randomized controlled trial","functional magnetic resonance imaging","Autobiographical Memory Test (AMT)","Major Depressive Disorder","Bipolar Disorder","RECRUITING","2026-05-27",{"date":48,"type":49},"2026-06-01","ACTUAL",{"date":51,"type":49},"2026-01-15",{"date":53,"type":21},"2028-08",{"name":55,"class":56},"Anders Jørgensen","OTHER",1,{"id":59,"slug":60,"hasResults":11,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":4,"eligibilityCriteria":64,"healthyVolunteers":11,"sex":17,"minAge":65,"maxAge":4,"enrollmentInfo":66,"targetDuration":4,"studyType":22,"phases":68,"briefSummary":69,"conditions":70,"keywords":4,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":57},"100492982","amplitude-titration-to-improve-ect-clinical-outcomes-100492982","NCT05699226","Amplitude Titration to Improve ECT Clinical Outcomes","Amplitude Titration to Improve ECT Clinical Outcomes Randomized Clinical Trial","Inclusion Criteria:\n\n* Diagnosis of major depressive disorder or bipolar II\n* Clinical indications for ECT with right unilateral electrode placement\n\nExclusion Criteria:\n\n* Defined neurological or neurodegenerative disorder (e.g., traumatic brain injury, epilepsy, Alzheimer's disease)\n* Other psychiatric conditions (e.g., schizophrenia, bipolar I disorder)\n* Current drug or alcohol use disorder (except for nicotine)\n* Contraindications to MRI.","50 Years",{"count":67,"type":21},50,[24],"A randomized controlled trial will compare hippocampal neuroplasticity, antidepressant, and cognitive outcomes between individualized amplitude and fixed 800 mA amplitude ECT in older depressed subjects (n = 25 per group, n = 50 total). Relative to fixed 800 mA ECT:\n\nH1: Individualized amplitude arm will have improved RUL antidepressant outcome (IDS-C30 response rates and reduced BT electrode placement switch at V2).\n\nH2: Individualized amplitude arm will have improved cognitive outcomes (DKEFS-Verbal Fluency",[71,33,72],"Depression","Cognitive Change","2026-01-23",{"date":75,"type":49},"2026-01-26",{"date":77,"type":49},"2023-09-14",{"date":79,"type":21},"2028-01-01",{"name":81,"class":56},"University of New Mexico",{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":17,"minAge":89,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":22,"phases":93,"briefSummary":95,"conditions":96,"keywords":4,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":108},"100612006","early-phase-1-subanesthetic-esketamine-in-modified-ect-for-severe-depression-in-adolescents-clinical-and-mechanistic-study-100612006","NCT07247968","Subanesthetic Esketamine in Modified ECT for Severe Depression in Adolescents: Clinical and Mechanistic Study","Clinical and Mechanistic Study of Subanesthetic-dose Esketamine in Modified Electroconvulsive Therapy for Adolescents With Severe Depression","Inclusion Criteria:\n\n* Inpatients diagnosed with Major Depressive Disorder according to the International Classification of Diseases,11th Revision(ICD-11),and scheduled for Modified Electroconvulsive Therapy(MECT);\n* Aged 13 to 17 years,regardless of gender;\n* Educational attainment of primary school or higher;\n* Normal hearing and vision,including color perception;\n* Voluntary participation in the study with signed informed consent;\n* American Society of Anesthesiologists(ASA)physical status classification I-II.\n\nExclusion Criteria:\n\n* Severe cardiovascular disease,significant arrhythmias,or other cardiac conditions;\n* Inability to complete the assessment scales;\n* History of substance abuse;\n* Received electroconvulsive therapy(ECT)within 6 months prior to the study;\n* Severe cerebrovascular disease,severe hypertension,intracranial hypertension,or presence of intracranial electrodes;\n* Severe allergy or contraindication to propofol or succinylcholine;\n* Comorbid with other psychiatric disorders.","13 Years","17 Years",{"count":92,"type":21},220,[94],"EARLY_PHASE1","The study design was a randomized, double blind, parallel controlled trial.The goal of this clinical trial is to learn if esketamine-assisted modified electroconvulsive therapy (ESK-MECT) works to treat severe depression in adolescents. It will also learn about the safety of ESK-MECT.\n\nThe sample size was calculated based on the response rate of patients with depression undergoing electroconvulsive therapy(ECT).According to the results of the pilot study,the efficacy rate of subjects receiving adjunctive esketamine was approximately 78%,while the efficacy rate of those receiving only propofol was 63%.The expected superiority difference in remission rates between the two groups was 15%(one-sided)for the power calculation.Assuming a significance level of α=0.05 and a test power of β=0.2,with a 1:1 ratio of sample sizes between the two groups,the total sample size was calculated to be 198 using the PASS software(PASS 2023).Considering a dropout rate of 10%,a total of 220 subjects were required,with 110 subjects in each group.\n\n1. experimental group The patients were given intravenous injection of 0.25 mg \u002F kg esketamine, 1.5 mg \u002F kg propofol and 1 mg \u002F kg succinylcholine in turn. After anesthesia, the patients were given electroconvulsive therapy.\n2. In the control group The patients were given normal saline consistent with esketamine injection volume, 1.5mg\u002Fkg of propofol and 1mg \u002F kg of succinylcholine. After anesthesia, the patients were given electroconvulsive therapy.\n\nEfficacy evaluation 1. Main efficacy indicators Response rate of depressive symptoms after MECT treatment Response is defined as two consecutive HAMD-24 scores ≤ 50% before treatment after receiving MECT treatment. The response rate is calculated as the number of patients who achieved as response divided by the total number of patients receiving MECT.In this study, the 24-item version of HAMD was utilized.\n\nParticipants will:\n\nBe randomly assigned to the esketamine group or the control group, and receive standard MECT treatment.\n\nHave seizure parameters, seizure duration, vital signs, and complications recorded.\n\nComplete psychiatric scale assessments, including HAMD-24, BSS, PANSS, WMS-RC and MoCA.\n\nBe assessed at the following time points: HAMD-24 and BSS after each treatment; PANSS after each treatment course;WMS-RC and MoCA before MECT and after one treatment course.\n\nAll subjects did not discontinue antidepressants before modified electroconvulsive therapy(MECT),and they were fasting for 8 hours and no fluids for 2 hours.Three minutes before MECT,continuous qCON monitoring(Apollo-9000A,Chongqing Xideer Medical Equipment Co.,Ltd.,China)was initiated,while monitoring blood pressure,heart rate,and peripheral capillary oxygen saturation.Preoxygenation was administered for 3 minutes.The qCON monitor uses three electrodes on the forehead to collect raw electroencephalogram(EEG)signals.The qCON monitoring includes the qCON index,qNOX index,burst suppression(BS),and signal quality index(SQI).",[97,33,71,98],"Esketamine","Adolescent","2026-01-06",{"date":101,"type":49},"2026-01-07",{"date":103,"type":49},"2025-11-25",{"date":105,"type":21},"2026-12-20",{"name":107,"class":56},"Min Su",2,{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":22,"phases":118,"briefSummary":119,"conditions":120,"keywords":122,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":57},"100514066","metabolomics-during-electroconvulsivotherapy-100514066","NCT05973643","Metabolomics During ElectroConvulsivoTherapy","Study by 1H NMR of the Variations of the Metabolome During the Course of Electroconvulsive Therapy in Patients With Major Depressive Episode","METECT","Inclusion Criteria:\n\n* Major depressive episode according to DSM-5 criteria\n* Diagnosis of major depressive disorder or bipolar disorder\n* MADRS score \\>22\n* having given written, free and informed consent\n* without protective measures\n* resistance criterion defined as failure of 2 antidepressants at an effective dose for a minimum of 6 weeks\n* current major depressive episode according to DSM-5 criteria with indication of treatment by ECT cure\n\nExclusion Criteria - Cannot be included in the study, people:\n\n* whose consent is not admissible or who refuse to participate in the study\n* deprived of liberty by judicial or administrative decision\n* For which there is a particular risk contraindicating the cure of ECT\n* Suffering from schizophrenia spectrum disorders or persistent delusional disorder as described by DSM-5 Criterion D for Major Depressive Disorder\n* suffering from neurological disorders (such as patients suffering from multiple sclerosis, epilepsy, encephalitis, etc.) and\u002For neurodegenerative disorders (such as Parkinson's disease, Alzheimer's disease or related diseases, etc.) as described by criterion C of the major depressive disorder listed in the DSM-5\n* suffering from an acute or chronic systemic inflammatory disease requiring specific treatment with immunomodulators or suppressors. As well as any recurrent inflammatory disease requiring specific management, and which may lead to a differential diagnosis of the characterized depressive episode as described by criterion C listed in the DSM-5",{"count":67,"type":21},[24],"Investigators will measure the variation of blood Metabolome through 1H NMR at several time points during the course of electroconvulsivetherapy in patients with a major depressive episode. Patients with a major depressive disorder or a bipolar disorder and a current major depressive episode will be included in this study. Investigators hypothesized that Metabolome could be a source to predict response during ECT and to help understanding underlying biological mechanisms.",[121,33],"Major Depressive Episode",[123,32,124],"1HNMR","Major Depression","2025-07-23",{"date":127,"type":49},"2025-07-24",{"date":129,"type":49},"2024-03-11",{"date":131,"type":21},"2026-10-15",{"name":133,"class":56},"Hôpital le Vinatier",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":142,"targetDuration":4,"studyType":22,"phases":144,"briefSummary":146,"conditions":147,"keywords":148,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":57},"100489640","phase-4-comparison-of-esketaminepropofol-and-methohexital-anesthesia-for-ect-100489640","NCT05655754","Comparison of Esketamine\u002FPropofol and Methohexital Anesthesia for ECT","A Prospective Randomized, Double Blind, Controlled, Safety and Non-inferiority Study of Esketamine Plus Propofol Compared to Methohexital Anesthesia for Electroconvulsive Therapy","Ketofol","Inclusion Criteria:\n\n* male or female inpatients\n* age ≥ 18 years\n* ICD-11 diagnosis of severe uni- or bipolar depression (F32.2, F32.2, F33.2, F33.3, F31.4, F31.5)\n* Hamilton Depression Rating Scale HAMD17 ≥ 24\n* ability to understand and willingness to sign written informed consent document\n* negative urine pregnancy test in women\n* anesthesiological approval for ECT (Classification of the American Society of Anesthesiologists ASA ≤ 3)\n* antidepressant and antipsychotic medication in steady state for at least 7 days prior to first ECT treatment\n\nExclusion Criteria:\n\n* severe somatic or neurological disease (esp. current or previous history of intracranial hypertension, uncontrolled severe hypertension, bleeds or aneurysm, recent myocardial infarction)\n* current or past history of schizophrenia or schizoaffective disorder\n* clinical relevant abnormalities on a general physical examination and routine laboratory screening\n* pregnancy, breast feeding\n* known allergy to the study drugs or compounds of the latter",{"count":143,"type":21},100,[145],"PHASE4","The current anesthetic drug used as standard for ECT procedure at the Department of Psychiatry and Psychotherapy, Medical University of Vienna, is the barbiturate methohexital (Brevital®). As far as we know, methohexital is the most common anesthetic in the procedure of ECT. Only few heterogeneous randomized controlled trials to directly compare the use of (sole) ketamine and methohexital in ECT with relatively small sample sizes have been conducted so far, showing inconclusive findings: a retrospective comparison of methohexital and switch to ketamine anesthesia in 36 patients showed that ketamine prolonged seizure duration and accelerated posttreatment orientation. Others compared both drugs in terms of recovery and reorientation time showing that reorientation time was faster in the methohexital group (total N=9). Another study showed no difference in any outcome measure (depressive symptom improvement, cognition, adverse events) between both groups (total N=16, N=9 per group). Finally, a comparative investigation (total N=37, N=20 vs. N=17) detected no differences between both anesthetics but a higher systolic blood pressure posttreatment and longer motor seizure duration in the ketamine group. A favorable profile of ketamine in regards to seizure quality has been reported, however in terms of outcome measures methohexital and ketamine were similar (total N=50, N=23 vs. N=27).\n\nThe present study is designed as a prospective randomized non-inferiority trial comparing esketamine plus propofol (ratio 1:1, for better readability from now on referred to as \"ketofol\") to methohexital, the latter being the current standard anesthetic applied for ECT procedure at our department. Patients eligible for ECT will be randomly assigned to receive anesthesia with either ketofol or methohexital for the whole course of the individual ECT series. Group differences will be investigated both in regards to outcomes related to anesthesia, treatment-outcome and seizure quality.\n\nFurther, changes in cardiac enzyme levels before and after ECT-treatment and during the entire ECT series will be evaluated and possible group differences will be explored.\n\nAs stated above the sole\u002Fadjunct administration of ketamine as anesthetic agent for ECT has been associated with better seizure quality, similar antidepressant outcomes and anesthesia-associated events, while there is some evidence suggesting that the use of ketamine might present some advantages to other anesthetics in terms of cognitive side-effects accompanying ECT. Therefore, the aim of the present study will be to establish ketofol as a new standard for anesthesia at our Department.",[33,71],[39,149,150,151],"depression","esketamine","anesthesia","2025-05-05",{"date":154,"type":49},"2025-05-08",{"date":156,"type":49},"2022-11-01",{"date":158,"type":21},"2025-10-31",{"name":160,"class":56},"Medical University of Vienna","Ect."]